TICKERNERD
Menu
RACCFinancial Services · Shell Companies

RACC Stock Forecast: Research Alliance Corp. III Price Predictions for 2026-2027

Last close, 22 Oct 2026
$10
−0.01% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 8 of 100 as at 22 Oct 2026 — in the weakest quartile.

Market cap
$92.2M
Ticker Nerd rank
8/ 100
Median analyst target
—
Analysts covering
—
Total return, dividends reinvested
1W
−0.3%
1M
−8.4%
From high
−65.4%
From low
0.0%
$10
$29
Range since 20 May 2026, adjusted closes · the dot is the last close
Ticker Nerd rank

RACC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Research Alliance Corp. III on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Oct 2026
8/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
74
Volatility
57
Value
50
Quality
28
Revisions
25
Issuance
22
Growth
16
Accruals
8
Momentum
6

Size (74): Smaller than most of the companies we track.

Momentum (6): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

RACC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RACC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 20 May 2026Adjusted close, US dollars
$10$15$20$25Jun 26Jul 26Aug 26Sep 26Oct 26RACC

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

RACC appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.
  • The AI build-out, every Wednesday: how AI stocks did, part by part.

Free. Unsubscribe any time.

Performance

RACC vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

RACC vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250Jun 26Jul 26Aug 26Sep 26Oct 26RACCS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

RACC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Research Alliance Corp. III (RACC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
0.7×

Cheaper than 79% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
—
Return on assets
−1290.5%

Higher than 1% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Research Alliance Corp. III (RACC) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Research Alliance Corp. III has a market value of $92.2M and an enterprise value of $91.3M.

  • Shares outstanding: 9.1M.

  • Forward dividend yield: 0.00%.

  • Research Alliance Corp. III employs 0 people.

market figures as at 22 Oct 2026

Data provided by Twelve Data

Peers

RACC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelShell Companies
CompanyMarket capTKN rank
RACCResearch Alliance Corp. III$92.2M8
SIMASIM Acquisition Corp. I$91.2M70
MMTXMiluna Acquisition Corp.$90.5M22
AMACAMR Resources Acquisition Corp.$94.0M5
FVNFuture Vision II Acquisition Corp.$90.4M33
FDMMFreedom Metals Acquisition Corp.$90.1M5
ORIQOrigin Investment Corp. I$90.0M41

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Research Alliance Corp. III — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest RACC news & analysis

Oak Hill Bio and Research Alliance Corporation III Announce Business Combination Agreement to Create Publicly Listed Rare Disease Biotechnology Company to Advance Antisense Oligonucleotide Therapy Rugonersen for Angelman Syndrome

GlobeNewsWire · 27 July 2026positive

Research Alliance Corporation III (RACC) announced a definitive business combination agreement with Oak Hill Bio to create a publicly listed rare disease biotechnology company focused on advancing rugonersen for Angelman syndrome.

Why it matters — This provides RACC with a merger target — Oak Hill Bio — and the deal is expected to fund development of rugonersen through Phase 3 readout and potential NDA submission in the second half of 2029.

FAQ

Frequently asked questions about RACC stock

How does Ticker Nerd's model rank RACC?

As at 22 Oct 2026, Research Alliance Corp. III ranks 8 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (74 of 100).

What is the RACC stock forecast for 2030?

No analyst covering Research Alliance Corp. III publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RACC are extrapolating price history, which says nothing about the business.

What does Research Alliance Corp. III do?

Research Alliance Corporation III Class A Ordinary Shares is the public equity of Research Alliance Corporation III, a special purpose acquisition company formed to pursue a business combination with one or more operating businesses. The Class A ordinary shares represent the company’s publicly traded ownership interests and are intended for investors participating in the SPAC structure while the company searches for a merger, share exchange, asset acquisition, or similar transaction.

What is the latest news on RACC?

The most recent item we track (GlobeNewsWire, 27 July 2026): "Oak Hill Bio and Research Alliance Corporation III Announce Business Combination Agreement to Create Publicly Listed Rare Disease Biotechnology Company to Advance Antisense Oligonucleotide Therapy Rugonersen for Angelman Syndrome". Research Alliance Corporation III (RACC) announced a definitive business combination agreement with Oak Hill Bio to create a publicly listed rare disease biotechnology company focused on advancing rugonersen for Angelman syndrome.

Company

About Research Alliance Corp. III.

Research Alliance Corporation III Class A Ordinary Shares is the public equity of Research Alliance Corporation III, a special purpose acquisition company formed to pursue a business combination with one or more operating businesses. The Class A ordinary shares represent the company’s publicly traded ownership interests and are intended for investors participating in the SPAC structure while the company searches for a merger, share exchange, asset acquisition, or similar transaction. Research Alliance Corporation III is organized as a Cayman Islands exempted company and is headquartered in New York. Its current market role is centered on capital formation and deal execution within the blank-check company segment, where proceeds are held for a future combination rather than for traditional operating business activities. The shares are used as the primary listed security for the company’s public market presence.

CEO Dr. Matthew D. Hammond M.B.A., Ph.D. · United States